RETROSPECTIVE ANALYSIS OF CLINICAL AND BIOCHEMICAL INDICATORS IN PATIENTS WITH METABOLIC SYNDROME WHO RECOVERED FROM COVID-19
Keywords:
Metabolic syndrome, COVID-19, carbohydrate metabolism, lipid metabolism, triglyceride-glucose indexAbstract
Complications associated with coronavirus disease (COVID-19) are significantly prevalent among patients with comorbid conditions such as hypertension, obesity, and diabetes.
Purpose of the Study: The aim of this study was to conduct a retrospective analysis of lipid profiles and carbohydrate metabolism in patients with a history of COVID-19 infection.
Materials and Methods: A retrospective analysis was performed on the clinical data of 215 patients treated at the Republican Specialized Scientific-Practical Medical Center of Endocrinology, who were included in the database from January to August 2022. Of these, 127 patients had confirmed COVID-19 diagnoses via polymerase chain reaction (PCR) testing for SARS-CoV-2, while 88 patients had no history of COVID-19. Patients lacking data on body mass index (BMI), blood pressure, triglycerides (TG), total cholesterol (TC), glucose levels, insulin, and C-reactive protein (CRP) were excluded from the study.
Results: Patients with metabolic syndrome (MS) who recovered from COVID-19 showed significantly more pronounced changes in hemodynamics (elevated systolic blood pressure), lipid metabolism (increased levels of TG, apolipoprotein B [ApoB], ApoB/ApoA1 ratio, and decreased levels of high-density lipoprotein cholesterol [HDL-C] and apolipoprotein A1 [ApoA1]), carbohydrate metabolism (elevated fasting glucose, insulin, and homeostatic model assessment of insulin resistance [HOMA-IR]), and inflammatory markers (elevated CRP) compared to patients with MS who had not contracted COVID-19 and those without MS who had recovered from COVID-19.
References
Abbasian M., Ebrahimi H., Delvarianzadeh M. et al. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes Metab Syndr. 2016; 10(3): 132-136. doi: 10.1016/j.dsx.2016.01.003.
Ansari-Moghaddam A., Adineh H., Zareban I., Farmanfarma K. Prevalence of metabolic syndrome and population attributable risk for cardiovascular, stroke, and coronary heart diseases as well as myocardial infarction and all-cause mortality in middle-east: Systematic review & meta-analysis. Obesity Medicine. 2019; 14: 100086. doi: 10.1016/j.obmed.2019.100086.
Arhipova E.V. Metabolicheskij sindrom: patogenez, kriterii diagnostiki i lechenie. Vestnik Buryatskogo gosudarstvennogo universiteta. Medicina i farmaciya. 2019; 2: 3‒9. doi: 10.18101/2306-1995-2019-2-3-9
Buber I., Nar R., Kaya D. et al. Assessment of triglyceride/glucose index with respect to coronary slow flow. Bratisl Lek Listy. 2022; 123(8): 585-588. doi: 10.4149/BLL 2022 095.
Chen L., Lin Z., Chen J. et al. Can elevated concentrations of ALT and AST predict the risk of 'recurrence' of COVID-19? Epidemiol Infect. 2020 Sep 21;148: e218. DOI: 10.1017/S0950268820002186
Chowdhury M., Anik A., Farhana Z. et al. Prevalence of metabolic syndrome in Bangladesh: a systematic review and meta-analysis of the studies. BMC Public Health. 2018; 18(1): 308. doi: 10.1186/s12889-018-5209-z.
Demidova T.YU., Izmajlova M.YA., Belova K.M. Rol' trigliceridno-glyukoznogo indeksa v opredelenii serdechno-sosudistogo i metabolicheskogo prognoza u pacientov s saharnym diabetom 2-go tipa. Medicinskij sovet. 2023; 17(9): 47–57. doi.org/10.21518/ ms2023-172.
Farmanfarma K., Kaykhaei M., Mohammadi M. et al. The Prevalence and Trend of Metabolic Syndrome in the South-East of Iran. J Med Life. 2020; 13(4): 587-599. doi: 10.25122/jml-2020-0052.
Hussain A., Bhowmik B., do Vale Moreira N. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020; 162: 108142. doi: 10.1016/j.diabres.2020.108142.
Khan S., Sobia F., Niazi N. et al. Metabolic clustering of risk factors: evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistance. Diabetol Metab Syndr. 2018; 10: 74. doi: 10.1186/s13098-018-0376-8.
Lee S., Han K., Kang Y. et al. Trends in the prevalence of metabolic syndrome and its components in South Korea: Findings from the Korean National Health Insurance Service Database (2009-2013). PLoS One. 2018; 13(3): e0194490. doi: 10.1371/journal.pone.0194490.
Li B., Yang F., Zhao J.et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020; 109(5): 531–538. doi: 10.1007/s00392-020-01626-9.
Li G., Chen Z., Lv Z. et al. Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. Int J Endocrinol. 2021; 1:7394378. doi: 10.1155/2021/7394378.
Najdenova A.G., Simeonov M.M., Atanasov A.M. i dr.Issledovanie associacii sootnoshenij mezhdu ApoB/ApoA1, TS/HDL-C, LDL-C/HDL-C i trigliciridami/ HDL-S i metabolicheskim sindromom v bolgarskoj populyacii. Evrazijskij Soyuz Uchenyh. 2016; 5(26): 52-60.
Nedogoda S.V., Ledyaeva A.A., Salasyuk A.S. i dr. Vliyanie perenesennogo COVID-19 na elastichnost' sosudov i funkciyu pecheni u pacientov s izbytochnoj massoj tela. Profilakticheskaya medicina. 2023; 26(2): 69–78. doi.org/10.17116/profmed20232602169
Scuteri A., Laurent S., Cucca F. et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015; 22(4): 486-491. doi: 10.1177/2047487314525529.
Tahani Masoud, Nasab Shiva Rakhshani, Shahramian Iraj et al. GGT Level as a New Biomarker of COVID-19 Infection; a Systematic Review and Meta-Analysis Comparing Intensive Care Unit (ICU) Patients with Non-ICU Cases. Infekc. bolezni (Infectious Diseases). 2023; 21(2): 47–56. (In Russian). doi: 10.20953/1729-9225-2023-2-47-56.
Yuksel Y., Yildiz C. Evaluation of triglyceride-glucose index in coronary slow flow patients. Kardiologiia. 2023; 63(5): 62-67. doi: 10.18087/cardio.2023.5.n2296.
Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020; 382(8):727–733. doi: 10.1056/nejmoa2001017.
